Institutional Profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics
- 1 May 2013
- journal article
- Published by Future Medicine Ltd in Pharmacogenomics
- Vol. 14 (7), 723-726
- https://doi.org/10.2217/pgs.13.59
Abstract
The University of Florida and Shands Hospital recently launched a genomic medicine program focused on the clinical implementation of pharmacogenetics called the Personalized Medicine Program. We focus on a pre-emptive, chip-based genotyping approach that is cost effective, while providing experience that will be useful as genomic medicine moves towards genome sequence data for patients becoming available. The Personalized Medicine Program includes a regulatory body that is responsible for ensuring that evidence-based examples are moved to clinical implementation, and relies on clinical decision support tools to provide healthcare providers with guidance on use of the genetic information. The pilot implementation was with CYP2C19–clopidogrel and future plans include expansion to additional pharmacogenetic examples, along with aiding in implementation in other health systems across Florida.Keywords
This publication has 5 references indexed in Scilit:
- Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping ArrayClinical Pharmacology & Therapeutics, 2012
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) GenotypeCancer Cell, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin DosingCancer Cell, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel TherapyCancer Cell, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine DosingClinical Pharmacology & Therapeutics, 2011